Different effects of oral and transdermal hormonal replacement on prostacyclin and thromboxane A2

Obstetrics and Gynecology

Volumn 89, Issue 1, 1997, Pages 104-107

  Viinikka, Lasse ^a   Orpana, Arto ^b   Puolakka, Jukka ^b   Pyörälä, Tapani ^b   Ylikorkala, Olavi ^b  

^a UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; 2,3 DINORTHROMBOXANE B2; 6 OXOPROSTAGLANDIN F1 ALPHA; CREATININE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PROSTACYCLIN; THROMBOXANE A2; THROMBOXANE B2;

ADULT; ARTICLE; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MIXTURE; FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION; TRANSDERMAL DRUG ADMINISTRATION; VASODILATATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; EPOPROSTENOL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDROXYPROGESTERONE; MIDDLE AGED; NORETHINDRONE; PROGESTERONE CONGENERS; THROMBOXANE A2;

EID: 0031012264     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(96)00379-1     Document Type: Article

References (24)

1. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-9.
2. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and risk of coronary heart disease in women. N Engl J Med 1987;316:1105-10.
3. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-9.
4. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988;159:312-7.
5. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis. Br J Obstet Gynaecol 1990;97:1080-6.
6. Grady D, Rubin SM, Petiti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent diseases and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
7. Lobo RA, Speroff L. International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil Steril 1994;61:592-5.
8. LaRossa JC. Has HRT come of age? Lancet 1995;345:76-7.
9. Pines A, Fisman EZ, Levo Y, Averbuch M, Lidor A, Drory Y, et al. The effects of hormone replacement therapy in normal postmenopausal women: Measurement of Doppler-derived parameters of aortic flow. Am J Obstet Gynecol 1991;164:806-12.
10. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993;342:133-6.
11. Vane JR, Änggård E, Botting RM. Regulatory functions of vascular endothelium. N Engl J Med 1990;323:27-36.
12. Ylikorkala O, Pekonen F, Viinikka L. Renal prostacyclin and thromboxane in normotensive and pre-eclamptic pregnant women and their infants. J Clin Endocrinol Metab 1987;63:1307-12.
13. Tulppala M, Viinikka L, Ylikorkala O. Thromboxane dominance and prostacyclin deficiency in habitual abortion. Lancet 1991;337: 879-81.
14. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II. A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979;54:74-9.
15. α by uterine arteries from postmenopausal women. Am J Obstet Gynecol 1989;161:1677-81.
16. Ylikorkala O, Hirvonen E, Saure A, Viinikka L. Urinary excretion of prostacyclin and thromboxane metabolites in climacteric women: Effect of estrogen-progestin replacement therapy. Prostaglandins 1990;39:33-7.
17. Foidart JM, Dombrowitz N, de Ligniéres B. Urinary excretion of prostacyclin and thromboxane metabolites in postmenopausal women treated with percutaneous estradiol (Oestrogel®) or conjugated estrogens (Premarin®). In: Dusitsin N, Notelovitz M, eds. Physiological hormone replacement therapy. Carnforth (UK): The Parthenon Publishing Co., 1990.
18. Witter FR, DiBlasi MC. Effect of steroid hormones on arachidonic acid metabolites of endothelial cells. Obstet Gynecol 1984;63:747-51.
19. Ylikorkala O, Puolakka J, Viinikka L. Vasoconstrictory thromboxane A2 and vasodilatory prostacyclin in climacteric women: Effect of oestrogen-progestogen therapy. Maturitas 1984;5:201-5.
20. 2 in humans. Am J Obstet Gynecol 1982;142:573-6.
21. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: Results of a case-control study. BMJ 1993;306:956-63.
22. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclo-oxygenase. N Engl J Med 1984;311:1206-11.
23. Chu G, Farrell GC. Portal vein thrombosis associated with prolonged ingestion of oral contraceptive steroids. J Gastroenterol Hepatol 1993;8:390-3.
24. Elam MB, Lipscomb GE, Chesney CM, Terragno DA, Terragno NA. Effect of synthetic estrogen on platelet aggregation and vascular release of PGI2-like material. Prostaglandins 1980;20: 1039-51.